by Plus Therapeutics | Apr 10, 2024 | Uncategorized
#ICYMI : “Plus Therapeutics (PSTV), the Healthcare sector company, was revisited by a Wall Street analyst…Analyst Justin Walsh from JonesTrading maintained a Buy rating on the stock and has a $32.00 price target. Justin Walsh has given his Buy rating due...
by Plus Therapeutics | Apr 9, 2024 | Social
Tweets by...
by Plus Therapeutics | Apr 9, 2024 | Uncategorized
We would like to officially welcome Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. to the Plus Therapeutics Management Team! “As we prepare for the future, Plus is substantially strengthening its management in key areas such as cancer biology,...
by Plus Therapeutics | Apr 8, 2024 | LM
Our ReSPECT-LM Poster from the National Comprehensive Network (NCCN) Conference is now on our website at https://ir.plustherapeutics.com/presentations
by Plus Therapeutics | Apr 5, 2024 | LM
Visit our poster at the National Comprehensive Cancer Network® (NCCN®) conference today and say hello to our clinical team! The poster will be available on our website after the conference
Recent Comments